Montserrat Plana

Instituto de Salud Carlos III — Spain

Immunology and Microbiology · Life Sciences

24h-index2.6kcitations99works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(61), HIV/AIDS Research and Interventions(28), HIV/AIDS drug development and treatment(24), Immune Cell Function and Interaction(20), SARS-CoV-2 and COVID-19 Research(15)

Publications97 total

Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents
2025
Is a second dose of yellow fever vaccine needed? A systematic review of humoral and cell-mediated immunity after revaccination
Journal of Travel Medicine·2025
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study
Human Vaccines & Immunotherapeutics·2025Open Access
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
Vaccine·2025· 1 citedOpen Access
Humoral and Cellular Immune Responses after a Heterologous SARS-CoV-2 Booster with the Protein-Based PHH-1V Vaccine in People with Immunocompromising Conditions: The RBDCOV HIPRA-HH-4 Study
SSRN Electronic Journal·2025Open Access
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium
Emerging Microbes & Infections·2024· 7 citedOpen Access
Author Correction: Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium
npj Vaccines·2024· 1 citedOpen Access
SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR
2024· 1 citedOpen Access
Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months
2024· 1 citedOpen Access
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium
npj Vaccines·2024· 11 citedOpen Access
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
2024· 3 citedOpen Access
Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)
Vaccines·2023Open Access
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
npj Vaccines·2023· 10 citedOpen Access
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
The Lancet Regional Health - Europe·2023· 31 citedOpen Access
The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses
Vaccines·2023· 9 citedOpen Access
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial
2022· 4 citedOpen Access
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
2022· 10 citedOpen Access
Letter to the Editor on the original article: Lower prevalence of congenital cytomegalovirus infection in Portugal: possible impact of COVID-19 lockdown?
European Journal of Pediatrics·2022· 3 citedOpen Access
Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
Vaccines·2021· 19 citedOpen Access
Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals
Vaccines·2021· 4 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Felipe García(31), José M. Gatell(23), Teresa Gallart(15), José Alcamı́(14), Alberto C. Guardo(10), María Ángeles Muñoz‐Fernández(9), Tomàs Pumarola(8), Núria Climent(8), Bonaventura Clotet(8), Javier López Jiménez(8), Anna Cruceta(7), Agathe León(7), Carmen Gómez(7), Beatriz Perdiguero(7), Mariano Estéban(7), Àlex Soriano(6), Elisa de Lazzari(6), Julià Blanco(6), Núria Gonzàlez(5), Juan Carlos López Bernaldo de Quirós(5)